OSI Bid Likely to Rise as Astellas Seeks Cancer Sales
March 9, 2010 by biotechbillboard.com
OSI Bid Likely to Rise as Astellas Seeks Cancer Sales
March 9 (Bloomberg) — OSI Pharmaceuticals Inc.’s status as one of the few U.S. biotechnology companies with income from an approved cancer drug likely will drive up the price Tokyo-based Astell…
Read more on MalaysiaNews.net
Comments
Feel free to leave a comment...
and oh, if you want a pic to show with your comment, go get a gravatar!
You must be logged in to post a comment.